Skip to content

Earnings yield at other companies

Pfizer logo
PfizerPFE
6.8%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-11.8%-4.5pp
AbbVie logo
AbbVieABBV
0.9%-0.2pp
Immunome logo
ImmunomeIMNM
-9.1%-3.9pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-13.6%-5.7pp
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-5.7%-2.6pp

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

Based on trailing twelve months.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s earnings yield?
SELLAS Life Sciences Group, Inc. (SLS) reported earnings yield of -3.9% in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s earnings yield changed year-over-year?
SELLAS Life Sciences Group, Inc.'s earnings yield increased by 86.0% year-over-year, from -27.6% to -3.9%.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s earnings yield?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s earnings yield has grown at a -22.7% compound annual growth rate (CAGR), from -18.2% to -5%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.